When a plan drops GLP-1 weight-loss coverage, 65.5% of considerers turn away from medicine, not to cash, yet 80.6% would switch plans to keep it
When a health plan drops GLP-1 weight-loss coverage, 65.5% of US GLP-1 considerers would turn to diet and exercise or put treatment off rather than take any medicine, and only 11.5% would pay a drug maker's $350 to $500 cash price (n=139, October 2026).
- Who was asked
- US GLP-1 considerers, 139 clones, US
- When
- October 2026 (fielded 4 October 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- Rather than ask whether people would pay out of pocket, the study put a specific loss in front of them (a $50 copay withdrawn, a $1,000 list price) and offered five concrete routes, then tested the two escape routes the market talks about most: a better plan at open enrollment and a compounded version online.
Section 01: What the panel said
- #
65.5%
65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price.
base 139
- #
47.6%
47.6% of considerers with household income under $50,000 would put treatment off, against 26.0% (13 of 50) of those on $50,000 or more.
base 42 · Household income under $50,000 · contrast
- #
80.6%
80.6% would be very likely to switch at open enrollment to a plan that keeps a $50 copay for $40 a month more in premium.
base 139 · contrast
- #
67.6%
67.6% would be uncomfortable taking a compounded GLP-1 from an online telehealth service instead of the branded medicine.
base 139 · caveat
65.5% of GLP-1 considerers would turn to diet, exercise or a program (34.5%) or put treatment off (30.9%) if their plan dropped weight-loss coverage; 11.5% would pay a drug maker's cash price.
02Where does GLP-1 demand go when a health plan stops paying?
Mostly away from medicine altogether. Asked to imagine they had decided to start a GLP-1 for weight loss and their plan then withdrew a $50 copay, leaving a list price of about $1,000 a month, 65.5% of US considerers (91 of 139) said they would try diet, exercise or a commercial program (34.5%) or simply put treatment off (30.9%). Only 11.5% would pay a drug maker's direct cash price of $350 to $500, 18.0% would ask their doctor about an older, cheaper medicine, and 5.0% would buy a compounded version online.
Cost is the whole story. Asked what would stop them paying for the medicine themselves, 129 of 139 named the monthly price; side effects were named by nobody, and doubts about the results by 5.
03Who is most likely to give up rather than look for another route?
The lower the household income, the more often the answer is to stop. Among considerers with a household income under $50,000, 47.6% would put treatment off (20 of 42), against 26.0% of those on $50,000 or more (13 of 50). The better-off group does not pay cash instead: its most common move is diet, exercise or a program (46.0%, 23 of 50), and only 4 of the 50 would pay a cash price.
04If people will not pay cash, will they pay for a better plan?
Overwhelmingly, yes. Offered another plan at open enrollment that kept a $50 copay for $40 a month more in premium, 80.6% (112 of 139) said they would be very likely to switch, and 88.5% likely or very likely. In their reasoning the clones did the arithmetic: $90 a month all in is under the ceiling most of them named, where $1,000 is not.
That is the more interesting reading of this study, and it is a reading rather than a forecast: the money people will spend on GLP-1 access is real, but it is the size of a premium increase, not of a cash price, so demand waits for coverage rather than moving to a cash channel.
05Do compounded GLP-1s catch the people a plan leaves behind?
Very few of them. Two thirds (67.6%, 94 of 139) would be uncomfortable taking a compounded GLP-1 bought through an online telehealth service instead of the branded medicine, and half (50.4%) very uncomfortable. Even among the 20.9% who would be comfortable, compounding is rarely the first move: only 7 of the 139 chose it when coverage went.
Section 06: What they said, and the interview line it rests on
“There is absolutely no way I would pay $1,000 a month, or even $350 to $500 a month. I'm living paycheck to paycheck, and the money for an out-of-pocket expense like that simply does not exist. Paying out of pocket for something optional is completely off the table for me. I am also very skeptical of taking medications in general and prefer natural approaches whenever possible, so I wouldn't jump to an older drug or compounded versions from an online service that I wouldn't feel totally safe with. If insurance stops covering it, I would just turn to doing things the old-fashioned way through diet and exercise. It might take longer, but it's free. I can go for a run, focus on buying healthier foods, drink more water, and make those lifestyle changes on my own without spending money I don't have.”
Predicted from this line in the interview
“I can get the same results, arguably more lasting results, if I do it the old-fashioned way, which would take more time, but could be free. I could go for a run and start buying healthier food and drinking more water. So I would not pay out of pocket for something I can do for free.”
“I would definitely have to put off weight-loss treatment for now. Honestly, I'm poor and I ain't got no money to be paying out of pocket for expensive medications. If my insurance isn't covering it, there is just no way I could afford $1,000 a month, or even $300 to $500 a month. Out-of-pocket costs are not for poor folks these days, and I don't have extra money to spare on other things. Plus, I hate taking pills anyway, so I'm not going to run to a doctor asking for older diet pills. If my insurance drops the coverage and won't pay for it, I'd just have to hold off and not do it.”
Predicted from this line in the interview
“it's very important to me right now for any medication that my insurance would cover it because I don't have any money. No extra to spare, really. So it would have to cover most or all of the medication because out of pocket is really not for the poor folks these days.”
“I would be very likely to switch plans. An extra $40 a month in premium plus a $50 copay is only $90 a month total, which is a huge savings compared to paying $1,000 out of pocket. I always prefer having insurance cover it, and I try to be smart and save money rather than spending extra when I don't need to. Since I'd consider around $300 a month a fair price to pay, $90 is well within my budget and makes complete financial sense.”
Predicted from this line in the interview
“I try to save money. I like to don't spend a lot like in in things that I don't really need and I prefer like save for the future”
Section 07: How much should you trust this?
What we would defend
- Most considerers would leave medicine altogether if coverage went: 91 of 139 chose diet, exercise, a program or putting treatment off, and the figure held across two pulls of the data.
- The income split: 20 of 42 under $50,000 would put treatment off, against 13 of 50 above it; both bases are over 30.
- Cost, not safety or doubt about results, is what stops self-pay: 129 of 139 named the monthly price and none named side effects.
What we would not
- The 11.5% cash-pay figure as a market size: 12 of the 16 cash payers are clones with no income profile on file, and only 4 of the 92 clones with income on file chose cash.
- That 80.6% would actually switch plans at enrollment: the question set out a $90 against $1,000 comparison, so it shows where people would look first, not what they would do with networks and inertia in play.
- The 92.8% naming cost as the barrier as a precise share; near-unanimity is read as direction only.
The main limitation
These are considerers answering a hypothetical in which they had already decided to start, so the page measures stated intent at the moment coverage disappears, not what people later do; 47 of the 139 clones have no income profile on file.
Section 08: How was this run?
| Segment | Clones |
|---|---|
| Age 18-29 | 5 |
| Age 30-44 | 40 |
| Age 45-64 | 47 |
| Age 65+ | 24 |
| Age not on file | 23 |
Question wording as fielded
- Suppose you had decided to start a GLP-1 weight-loss medicine and your health plan would have covered it at a $50 monthly copay, but before you start the plan announces it will stop covering GLP-1 medicines for weight loss, leaving the list price of about $1,000 a month to you. What would you most likely do instead?
- If your health plan dropped GLP-1 weight-loss coverage, and at the next open enrollment another plan available to you still covered GLP-1 weight-loss medicines at a $50 monthly copay but cost $40 a month more in premium, how likely would you be to switch to that plan? (1 to 5)
- What would most likely stop you paying for a GLP-1 weight-loss medicine entirely out of your own pocket?
- How comfortable would you be taking a compounded GLP-1 weight-loss medicine bought through an online telehealth service instead of the branded medicine your doctor would prescribe? (1 to 5)
What was not asked, and why
No brand was named and no manufacturer's program was described, so the cash option is a price range, not a product. We did not ask about employer or state plan policy, about current users losing coverage mid-course (an earlier page covers past users), or about price points below $350.
What changed from the obvious question
Rather than ask whether people would pay out of pocket, the study put a specific loss in front of them (a $50 copay withdrawn, a $1,000 list price) and offered five concrete routes, then tested the two escape routes the market talks about most: a better plan at open enrollment and a compounded version online.
Fielded through Ask Brox on 4 October 2026.
More on GLP-1: starting, stopping and restarting · Pricing and price sensitivity · Pharma & HCP · GLP-1 Considerers (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
After stopping a GLP-1, 67.5% keep the weight off by changing their diet on their own and 17.5% by fitness; a $29 maintenance program would draw 62.0%, a $149 one 19.3%
67.5% 67.5% of past GLP-1 users rely most on eating less or eating differently on their own to keep the weight off, and 17.5% on exercise or a fitness routine. (base 166)
Read -
Why past GLP-1 users stop, and what brings them back: side effects (35.3%) and cost (31.2%) lead, and the fix must match the reason, with 94.3% of cost quitters wanting coverage under $50 and 60.0% of side-effect quitters a lower dose
35.3% 35.3% of US past GLP-1 users say side effects were the main reason they stopped, and 31.2% the monthly cost or losing insurance coverage (base 170)
Read -
GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%
37.5% 37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. (base 200)
Read -
GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month
70.8% 70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%). (base 137)
Read